Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LXRX Lexicon Pharmaceuticals

Market Closed 04-17 16:00:00 EDT

0.5098

+0.0098

+1.96%

盘后0.5100

+0.0002+0.04%

19:59 EDT

High0.5262	Low0.4980	Vol2.67M
Open0.5001	D1 Closing0.5000	Amplitude5.64%
Mkt Cap184.29M	Tradable Cap92.93M	Total Shares361.49M
T/O1.36M	T/O Rate1.47%	Tradable Shares182.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"LXRX","market":"US","secType":"STK","nameCN":"Lexicon Pharmaceuticals","latestPrice":0.5098,"timestamp":1744920000000,"preClose":0.5,"halted":0,"volume":2671184,"hourTrading":{"tag":"盘后","latestPrice":0.51,"preClose":0.5098,"latestTime":"19:59 EDT","volume":33879,"amount":17182.24921,"timestamp":1744934386810},"delay":0,"floatShares":182278260,"shares":361492295,"eps":-0.626198,"marketStatus":"Market Closed","change":0.0098,"latestTime":"04-17 16:00:00 EDT","open":0.5001,"high":0.5262,"low":0.498,"amount":1358202.236968,"amplitude":0.0564,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.626198,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":955080000000,"exchange":"NASDAQ","adjPreClose":0.5,"preHourTrading":{"tag":"盘前","latestPrice":0.5049,"preClose":0.5,"latestTime":"09:21 EDT","volume":19430,"amount":9839.8972058,"timestamp":1744896100607},"postHourTrading":{"tag":"盘后","latestPrice":0.51,"preClose":0.5098,"latestTime":"19:59 EDT","volume":33879,"amount":17182.24921,"timestamp":1744934386810},"volumeRatio":0.47048795876422367,"impliedVol":1.8017,"impliedVolPercentile":0.7649},"requestUrl":"/m/hq/s/LXRX","defaultTab":"news","newsList":[{"id":"2524460415","title":"LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524460415","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524460415?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 22:18","pubTimestamp":1743603480,"startTime":"0","endTime":"0","summary":"Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week.Per the deal terms, Lexicon will complete certain preclinical activities before Novo Nordisk takes over the development, manufacturing and commercialization of LX9851. NVO will also be responsible for LX9851’s investigational new drug  filing.In return, LXRX is eligible to receive $75 million as an upfront payment from NVO. Including milestone payments, the deal is worth up to $1 billion. Lexicon will also earn tiered royalties on potential net sales of the drug.Post the above setback, LXRX decided to discontinue developing the drug for the T1D indication and announced plans to reduce its workforce by 60%.A couple of better-ranked stocks from the sector are ANI Pharmaceuticals ANIP and 89bio ETNB. ANIP sports a Zacks Rank #1  at present and ETNB carries a Zacks Rank #2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lxrx-stock-moves-30-week-141800883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","ETNB","BK4139","ANIP","BK4599","NVO","IE00BKVL7J92.USD","LU0154236417.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4007","LXRX","BK4588","BK4532","LU1093756168.USD"],"gpt_icon":1},{"id":"2524607354","title":"Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2524607354","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524607354?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 20:00","pubTimestamp":1743595200,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, Texas, April 02, 2025  -- Lexicon Pharmaceuticals, Inc.  today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, April 9, at 8:00 a.m. ET.For Investor and Media Inquiries:Lisa DeFrancescoLexicon Pharmaceuticals, Inc.lexinvest@lexpharma.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexicon-pharmaceuticals-present-24th-annual-120000661.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LXRX","HCSG","BK4137","BK4139"],"gpt_icon":0},{"id":"2524913471","title":"Social Buzz: Wallstreetbets Stocks Mixed Premarket Tuesday; Tesla to Advance, Lexicon Pharmaceuticals to Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2524913471","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524913471?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 18:47","pubTimestamp":1743504466,"startTime":"0","endTime":"0","summary":"The most-talked-about stocks in the Reddit subforum Wallstreetbets were mixed hours before Tuesday's opening bell.Tesla  advanced by 2.4% in premarket hours, swinging from a 1.7% decline at Monday's close.Antero Midstream  rose by 2.2% in pre-bell activity, following a 0.3% increase from the previous session.DTE Energy  was 0.5% higher premarket, following a 1.2% rise at Monday's close.Boyd Gaming  advanced by 0.3% pre-bell, swinging from a 0.6% decline at Monday's close.Nvidia  was up 0.2% hours before before market open, swinging from a 1.2% fall at Monday's close.Lexicon Pharmaceuticals  declined by 1.8% premarket, after closing Monday with a 19.2% fall.Apple  was down 1.1% in pre-bell hours, swinging from a 1.9% increase at Monday's close.JPMorgan Chase  was 0.6% lower premarket, swinging from a 1% rise at Monday's close.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0347712357.USD","IE00BZ199S13.USD","LU0444973449.USD","LU2063271972.USD","LXRX","NVDD","IE00BJTD4N35.SGD","IE0003U64NQ7.SGD","LU1868837136.USD","IE0004445239.USD","NVD2.UK","TSYW.SI","SG9999015952.SGD","LU1084165304.USD","NVDU","NVDX","LU0256863811.USD","LU1046421795.USD","NVDS","LU0211326755.USD","LU2125154935.USD","LU0203345920.USD","IE00BDRTCR15.USD","DTE","SNVD.UK","2NVD.UK","BK4527","IE00BJTD4V19.USD","NVIW.SI","LU1934455277.USD","NVDY","NVD3.UK","LU0949170772.SGD","MACW.SI","LU0109391861.USD","3NVD.UK","BYD","NVDS.UK","LU0882574139.USD","AM","LU1974910355.USD","TSLA","LU1914381329.SGD","LU0353189680.USD","LU1003077747.HKD","TSLL"],"gpt_icon":1},{"id":"2523918680","title":"US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2523918680","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523918680?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 17:29","pubTimestamp":1743413398,"startTime":"0","endTime":"0","summary":"U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benchmark indices were lower in premarket.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/03/44556580/us-stocks-likely-to-open-lower-after-three-day-fall-equity-drawdown-probability-hasnt-peaked-yet-says-goldman-sachs-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4009","TGL","USAW.SI","BK4561","EQR","TIC","SH","PVH","IE00B19Z4B17.USD","USJW.SI","LU0048573561.USD","AIR","IVV","SPY","SDS","ESmain","SPXU","LOAR","TSYW.SI","BK4215","MNQmain","IE00B19Z3B42.SGD","BK4585","VOO","OEF","BW",".SPX",".IXIC","BK4202","LU0742534661.SGD","OEX","NQmain","LU1868837136.USD","LXRX","NVIW.SI","XOS","PSQ","LU2750360641.GBP","QID","QLD","BK4593","LU2237443895.HKD","LU0061475181.USD","PRGS","TQQQ","UPRO","SQQQ","SSO"],"gpt_icon":1},{"id":"2523686722","title":"BUZZ-U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, Wolfspeed","url":"https://stock-news.laohu8.com/highlight/detail?id=2523686722","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523686722?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 01:47","pubTimestamp":1743184057,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, WolfspeedEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL6N3QB0IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDS","ON","NVIW.SI","ECX","AGX","XPO","OXM","NVDU","LDOS","LGMK","LXRX","NVDX","LUV","X","2NVD.UK","3NVD.UK","SNVD.UK","NEM","NVD2.UK","SGHC","CVAC","GHLD","STSS","NVDD","ENPH","AIR","BEAM","PTCT","WRB","NVD3.UK","NVDY","NVD","WOLF","GME","MIST","AU","NVDS.UK","MRK","CPT","DTC"],"gpt_icon":1},{"id":"2522501104","title":"Lexicon Pharmaceuticals Shares up 65% on Licensing Deal With Novo Nordisk for Obesity Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522501104","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522501104?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 23:13","pubTimestamp":1743174807,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB1BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2522503339","title":"Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2522503339","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522503339?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 22:09","pubTimestamp":1743170940,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.Shares of Lexicon, based in The Woodlands, Texas, were recently changing hands at 60.4 cents, up 74%.Lexicon said the agreement gives Novo Nordisk an exclusive, worldwide license to develop, manufacture and commercialize LX9851, which is in development for the treatment of obesity and associated cardiometabolic disorders.Lexicon said it will receive an upfront payment of $45 million from Novo Nordisk, which makes the blockbuster weight-loss drugs Ozempic and Wegovy.Lexicon is also eligible for up to $960 million in development, regulatory and sales milestone payments, along with royalties on sales of LX9851.Lexicon last year said preclinical data show that LX9851 significantly reduced weight, food intake and fat mass in mice when combined with semaglutide, the key ingredient in Ozempic and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVO","LXRX"],"gpt_icon":1},{"id":"2522573061","title":"BUZZ-Lexicon surges on licensing deal with Novo Nordisk for obesity drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522573061","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522573061?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:06","pubTimestamp":1743163570,"startTime":"0","endTime":"0","summary":"BUZZ-Lexicon surges on licensing deal with Novo Nordisk for obesity drug ** Shares of drug developer Lexicon Pharmaceuticals LXRX.O jump 108% to 72 cents premarket ** LXRX says it has entered into an ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL3N3QB0WV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2522573982","title":"Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2522573982","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522573982?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:00","pubTimestamp":1743163226,"startTime":"0","endTime":"0","summary":"UPDATE 3-Novo Nordisk to license obesity drug from Lexicon in up to $1 billion dealAdds analyst comment in paragraph 9By Sneha  S K. Novo Nordisk NOVOb.CO is licensing Lexicon Pharmaceuticals' LXRX.O experimental obesity drug in a deal worth up to $1 billion, the Danish drugmaker's second deal this week, as it looks to strengthen the pipeline of its weight-loss treatments.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"4a641e4e4a3f19d0d6240caa73da3835","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL3N3QB0WG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LXRX","03933","BK4139"],"gpt_icon":0},{"id":"2522578447","title":"BRIEF-Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851","url":"https://stock-news.laohu8.com/highlight/detail?id=2522578447","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522578447?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:49","pubTimestamp":1743162596,"startTime":"0","endTime":"0","summary":"BRIEF-Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851March 28 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:LEXICON PHARMACEUTICALS ANNOUNCES EXCLUSIVE LICE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUAC1H3XW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2522200455","title":"Lexicon Pharmaceuticals Shares up 70% Premarket on Licensing Deal With Novo Nordisk for Obesity Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522200455","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522200455?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:40","pubTimestamp":1743162049,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0GH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2522224573","title":"Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851","url":"https://stock-news.laohu8.com/highlight/detail?id=2522224573","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522224573?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:30","pubTimestamp":1743161400,"startTime":"0","endTime":"0","summary":"Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments. THE WOODLANDS, Texas, March 28, 2025  -- Lexicon Pharmaceuticals, Inc.  today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. Lexicon will be responsible for completing agreed upon Investigational New Drug  application-enabling activities for LX9851. Novo Nordisk will be responsible for filing the IND, all further development, manufacturing and commercialization of LX9851.Lexicon is eligible to receive upfront and near-term milestone payments of up to $75 million. In total, Lexicon will be eligible to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"4a641e4e4a3f19d0d6240caa73da3835","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexicon-pharmaceuticals-announces-exclusive-license-113000573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756325.SGD","LU0154236417.USD","LU1093756168.USD","NVO","LXRX","BK4585","BK4139","IE00BZ1G4Q59.USD","BK4599","BK4532","BK4007","BK4588","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2522359769","title":"Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522359769","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522359769?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 02:55","pubTimestamp":1743015359,"startTime":"0","endTime":"0","summary":"The Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) share price has fared very poorly over the last month, falling by a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals/news/investors-dont-see-light-at-end-of-lexicon-pharmaceuticals-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B3QW5Z07.USD","USAW.SI","NDAQ","TQQQ","MNQmain","BK4211","NQmain","BK4585","BK4112","USJW.SI","QID",".IXIC","LXRX","ISBC","LU2210149790.SGD","QLD","BK4588","TSYW.SI","PSQ","NVIW.SI","BK4139","LU2095319765.USD","LU2210150020.SGD","SQQQ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD"],"gpt_icon":1},{"id":"2518762071","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: BridgeBio Pharma (BBIO), Johnson & Johnson (JNJ) and Lexicon Pharmaceuticals (LXRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518762071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518762071?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 15:31","pubTimestamp":1741678265,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BridgeBio Pharma (BBIO – Research Report), Johnson...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-bridgebio-pharma-bbio-johnson-johnson-jnj-and-lexicon-pharmaceuticals-lxrx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-bridgebio-pharma-bbio-johnson-johnson-jnj-and-lexicon-pharmaceuticals-lxrx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1280957306.USD","LU1066053197.SGD","BK4534","LU1162221912.USD","LU2430703095.HKD","JNJ","LU1935042991.SGD","IE00BJT1NW94.SGD","BK4581","LU0889566641.SGD","LU1894683348.USD","LU0098860793.USD","BK4139","LU0795875086.SGD","LU1059921491.USD","LU1261432733.SGD","LU2430703251.USD","BK4550","IE00B19Z3B42.SGD","LU1732800096.USD","LU0345770308.USD","LU1674673691.USD","HCSG","IE00B4R5TH58.HKD","IE0034235303.USD","BK4585","LU0792757196.USD","IE00B3PB1722.GBP","LU0345769631.USD","IE0002141913.USD","BK4559","LU1244550577.SGD","IE00BVYPNV92.GBP","LU1023059063.AUD","BK4533","LU0234570918.USD","LXRX","LU0234572021.USD","BK4007","LU1914381329.SGD","LU1267930813.SGD","LU1778281490.HKD","LU0882574055.USD","LU2129689514.USD","IE00BDGV0183.EUR","BBIO","BK4504","LU1718418525.SGD","LU0114720955.EUR","SG9999002232.USD"],"gpt_icon":0},{"id":"2518477001","title":"Lexicon Pharmaceuticals Faces Supply Chain Risks Amidst Changing Trade Policies","url":"https://stock-news.laohu8.com/highlight/detail?id=2518477001","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518477001?lang=en_us&edition=full_marsco","pubTime":"2025-03-09 14:00","pubTimestamp":1741500059,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (LXRX) has disclosed a new risk, in the Capital Markets category. Lexicon Pharmaceuticals faces significant business risks ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-faces-supply-chain-risks-amidst-changing-trade-policies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-faces-supply-chain-risks-amidst-changing-trade-policies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2517493411","title":"Lexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2517493411","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517493411?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 08:19","pubTimestamp":1741393154,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (($LXRX)) has held its Q4 earnings call. Read on for the main highlights of the call. The recent earnings call for Lexicon ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-mixed-earnings-call-achievements-and-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-mixed-earnings-call-achievements-and-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX"],"gpt_icon":0},{"id":"2517437582","title":"Lexicon Pharma Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2517437582","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517437582?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 23:51","pubTimestamp":1741362660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 10:51 ET (15:51 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"gpt_icon":0},{"id":"2517438278","title":"Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438278","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438278?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:30","pubTimestamp":1741354200,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, Texas, March  07, 2025  (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink Partn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038933/0/en/Lexicon-Pharmaceuticals-to-Present-at-the-Leerink-Partners-Global-Healthcare-Conference-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","HCSG","BK4137","BK4139"],"gpt_icon":0},{"id":"2517057484","title":"Lexicon Pharma Price Target Maintained With a $4.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517057484","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517057484?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 20:12","pubTimestamp":1741349520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 07:12 ET (12:12 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"gpt_icon":0},{"id":"2517048188","title":"Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517048188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517048188?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 19:51","pubTimestamp":1741348303,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on VYNE Therapeutics (VYNE – Research Report), Lexico...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vyne-therapeutics-vyne-lexicon-pharmaceuticals-lxrx-and-xtant-medical-holdings-xtnt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vyne-therapeutics-vyne-lexicon-pharmaceuticals-lxrx-and-xtant-medical-holdings-xtnt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4007","BK4139","BK4198","VYNE","HCSG","LXRX","XTNT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lexpharma.com","stockEarnings":[{"period":"1week","weight":0.0293},{"period":"1month","weight":0.4181},{"period":"3month","weight":-0.2612},{"period":"6month","weight":-0.7549},{"period":"1year","weight":-0.6853},{"period":"ytd","weight":-0.3097}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.52,"avgChangeRate":0.042172},{"month":2,"riseRate":0.4,"avgChangeRate":-0.059177},{"month":3,"riseRate":0.48,"avgChangeRate":-0.019425},{"month":4,"riseRate":0.44,"avgChangeRate":-0.006421},{"month":5,"riseRate":0.52,"avgChangeRate":0.035958},{"month":6,"riseRate":0.64,"avgChangeRate":0.119795},{"month":7,"riseRate":0.48,"avgChangeRate":0.017089},{"month":8,"riseRate":0.24,"avgChangeRate":-0.027412},{"month":9,"riseRate":0.32,"avgChangeRate":0.002483},{"month":10,"riseRate":0.52,"avgChangeRate":-0.007629},{"month":11,"riseRate":0.36,"avgChangeRate":-0.04494},{"month":12,"riseRate":0.48,"avgChangeRate":0.072476}],"exchange":"NASDAQ","name":"Lexicon Pharmaceuticals","nameEN":"Lexicon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lexicon Pharmaceuticals,LXRX,Lexicon Pharmaceuticals股票,Lexicon Pharmaceuticals股票老虎,Lexicon Pharmaceuticals股票老虎国际,Lexicon Pharmaceuticals行情,Lexicon Pharmaceuticals股票行情,Lexicon Pharmaceuticals股价,Lexicon Pharmaceuticals股市,Lexicon Pharmaceuticals股票价格,Lexicon Pharmaceuticals股票交易,Lexicon Pharmaceuticals股票购买,Lexicon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction